Rebamipide sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527782

CAS#: 169809-59-0 (sodium)

Description: Rebamipide is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals,[3] and temporarily activating genes encoding cyclooxygenase-2. Studies have shown that rebamipide can fight the damaging effects of NSAIDs on the GIT mucosa, and more recently, the small intestine, but not for naproxen-induced gastric damage.

Chemical Structure

img
Rebamipide sodium
CAS# 169809-59-0 (sodium)
Instruction

Theoretical Analysis

MedKoo Cat#: 527782
Name: Rebamipide sodium
CAS#: 169809-59-0 (sodium)
Chemical Formula: C19H14ClN2NaO4
Exact Mass: 370.07
Molecular Weight: 392.771
Elemental Analysis: C, 58.10; H, 3.59; Cl, 9.03; N, 7.13; Na, 5.85; O, 16.29

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 111911-87-6 (deleted)   90098-04-7 (free acid)   169809-59-0 (sodium)    

Synonym: Mucosta; OPC 12759; OPC-12759; OPC12759; Proamipide; Rebamipide; Rebator; Rebamipide sodium;

IUPAC/Chemical Name: sodium 2-[(4-Chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoate

InChi Key: GJOZVJFEEGNZID-UHFFFAOYSA-M

InChi Code: InChI=1S/C19H15ClN2O4.Na/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15;/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26);/q;+1/p-1

SMILES Code: O=C([O-])C(NC(C1=CC=C(Cl)C=C1)=O)CC2=CC(NC3=C2C=CC=C3)=O.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 392.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ballesteros-Sánchez A, Sánchez-González MC, De-Hita-Cantalejo C, Gutiérrez- Sánchez E, Rocha-de-Lossada C, Sánchez-González JM. The Efficacy and Safety of Rebamipide Ophthalmic Suspension (OPC-12759) in Patients with Dry Eye Disease: A Systematic Review of Randomized Controlled Trials. J Clin Med. 2023 Nov 17;12(22):7155. doi: 10.3390/jcm12227155. PMID: 38002767; PMCID: PMC10672675.


2: Kovaleva A, Poluektova E, Maslennikov R, Karchevskaya A, Shifrin O, Kiryukhin A, Tertychnyy A, Kovalev L, Kovaleva M, Lobanova O, Kudryavtseva A, Krasnov G, Fedorova M, Ivashkin V. Effect of Rebamipide on the Intestinal Barrier, Gut Microbiota Structure and Function, and Symptom Severity Associated with Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Randomized Controlled Trial. J Clin Med. 2023 Sep 20;12(18):6064. doi: 10.3390/jcm12186064. PMID: 37763004; PMCID: PMC10531936.


3: Dai X, Qin B, Zhang H, Zhao H, Zhao H, Huang L, Cheng J, Liu Z, Chen X. Determination of rebamipide in human plasma by a validated liquid chromatography-tandem mass spectrometry: Application in pharmacokinetics research. Pak J Pharm Sci. 2023 Jul;36(4(Special)):1281-1290. PMID: 37606017.


4: Eom Y, Chung SH, Chung TY, Kim JY, Choi CY, Yoon KC, Ko BY, Kim HK, Kim MK, Lee HK, Song JS, Hyon JY, Seo KY, Lee JS, Kim HM. Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial. BMC Ophthalmol. 2023 Aug 3;23(1):343. doi: 10.1186/s12886-023-03004-1. PMID: 37537533; PMCID: PMC10398964.


5: Bakulina NV, Tikhonov SV, Okovityi SV, Lutaenko EA, Bolshakov AO, Prikhodko VA, Nekrasova AS. [Pharmacokinetics and pharmacodynamics of rebamipide. New possibilities of therapy: A review]. Ter Arkh. 2023 Jan 16;94(12):1431-1437. Russian. doi: 10.26442/00403660.2022.12.202000. PMID: 37167190.


6: Elwany NE, El Salem A, Mostafa Mohamed N, Khalil SS, Mahmoud NM. Rebamipide protects against experimentally induced intestinal ischemia/reperfusion-promoted liver damage: Impact on SIRT1/β-catenin/FOXO1and NFκB signaling. Int Immunopharmacol. 2023 Jun;119:110269. doi: 10.1016/j.intimp.2023.110269. Epub 2023 May 4. PMID: 37148771.


7: Abdel-Fattah MM, Hassanein EHM, Sayed AM, Alsufyani SE, El-Sheikh AAK, Arab HH, Mohamed WR. Targeting SIRT1/FoxO3a/Nrf2 and PI3K/AKT Pathways with Rebamipide Attenuates Acetic Acid-Induced Colitis in Rats. Pharmaceuticals (Basel). 2023 Apr 2;16(4):533. doi: 10.3390/ph16040533. PMID: 37111290; PMCID: PMC10142103.


8: Jain K, Jaju M, Yadav D. Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre. Indian J Ophthalmol. 2023 Apr;71(4):1598-1602. doi: 10.4103/IJO.IJO_2586_22. PMID: 37026308; PMCID: PMC10276702.


9: Jang DJ, Lee JH, Kim DH, Kim JW, Koo TS, Cho KH. The Development of Super- Saturated Rebamipide Eye Drops for Enhanced Solubility, Stability, Patient Compliance, and Bioavailability. Pharmaceutics. 2023 Mar 15;15(3):950. doi: 10.3390/pharmaceutics15030950. PMID: 36986811; PMCID: PMC10053044.


10: Won YH, Goo YT, Sin GH, Hong SH, Kim CH, Kim MJ, Lee TH, Choi YW. Immediate- release tablet formulation of rebamipide and a pharmacokinetic study in healthy human subjects. Int J Clin Pharmacol Ther. 2023 Jun;61(6):273-288. doi: 10.5414/CP204329. PMID: 36971320.


11: Correction to "Rebamipide potentially mitigates methotrexate-induced nephrotoxicity via inhibition of oxidative stress and inflammation: A molecular and histochemical study". Anat Rec (Hoboken). 2023 Aug;306(8):2208-2209. doi: 10.1002/ar.25184. Epub 2023 Mar 7. Erratum for: Anat Rec (Hoboken). 2021 Mar;304(3):647-661. PMID: 36880452.


12: Hasan S, Perween N, Saeed S, Kaur M, Gombra V, Rai A. Evaluation of 5% Amlexenox Oral Paste and Rebamipide Tablets in Treatment of Recurrent Apthous Stomatitis and Comparison with Dologel CT. Indian J Otolaryngol Head Neck Surg. 2022 Dec;74(Suppl 3):5228-5234. doi: 10.1007/s12070-020-01858-1. Epub 2020 Apr 27. PMID: 36742475; PMCID: PMC9895324.


13: Bae S, Huh KY, Oh J, Yu KS, Kim A. Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration. Pharmaceuticals (Basel). 2023 Jan 16;16(1):132. doi: 10.3390/ph16010132. PMID: 36678630; PMCID: PMC9862565.


14: Jhun J, Moon J, Kim SY, Cho KH, Na HS, Choi J, Jung YJ, Song KY, Min JK, Cho ML. Rebamipide treatment ameliorates obesity phenotype by regulation of immune cells and adipocytes. PLoS One. 2022 Dec 27;17(12):e0277692. doi: 10.1371/journal.pone.0277692. PMID: 36574392; PMCID: PMC9794058.


15: Jia RJ, Wang XP, Zhang ZH, Cui HH, Qin R, Du DY, Liu Y. Effect of Rabeprazole and Rebamipide in the Treatment of Upper Gastrointestinal Hemorrhage Associated with Dual Antiplatelet Therapy in Elderly Patients with Coronary Heart Disease. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221130746. doi: 10.1177/10760296221130746. PMID: 36411982; PMCID: PMC9703470.


16: Oh DJ, Yoon H, Kim HS, Choi YJ, Shin CM, Park YS, Kim N, Lee DH, Ha YJ, Kang EH, Lee YJ, Kim N, Kim KJ, Liu F. The effect of rebamipide on non-steroidal anti-inflammatory drug-induced gastro-enteropathy: a multi-center, randomized pilot study. Korean J Intern Med. 2022 Nov;37(6):1153-1166. doi: 10.3904/kjim.2021.216. Epub 2022 Nov 1. PMID: 36375487; PMCID: PMC9666262.


17: Corrigendum to 'Rebamipide suppresses TNF-α; mediated inflammation in vitro and attenuates the severity of dermatitis in mice'. FEBS J. 2023 Mar;290(6):1663-1664. doi: 10.1111/febs.16654. Epub 2022 Oct 26. Erratum for: FEBS J. 2015 Jun;282(12):2317-26. PMID: 36288791.


18: Zaky HS, Abdel-Sattar SA, Allam A, Ahmed HI. Further insights into the impact of rebamipide on gentamicin-induced nephrotoxicity in rats: modulation of SIRT1 and β-catenin/cyclin D1 pathways. Drug Chem Toxicol. 2023 Nov;46(5):851-863. doi: 10.1080/01480545.2022.2104867. Epub 2022 Jul 28. PMID: 35899710.


19: Teshigawara T, Meguro A, Mizuki N. Impact of Perioperative Dry Eye Treatment with Rebamipide Versus Artificial Tears on Visual Outcomes After Cataract Surgery in Japanese Population. Ophthalmol Ther. 2022 Aug;11(4):1479-1491. doi: 10.1007/s40123-022-00523-w. Epub 2022 May 19. PMID: 35588046; PMCID: PMC9253222.


20: Jang E, Park M, Jeong JE, Lee JY, Kim MG. Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease. Sci Rep. 2022 May 12;12(1):7839. doi: 10.1038/s41598-022-11505-0. PMID: 35552457; PMCID: PMC9098635.